로딩 중...
52주 최고가 대비 43.5% 위치
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $12.68B | $14.24B | $16.75B | $20.07B |
| 영업이익 | - | $2.03B | $2.42B | $3.00B | $3.97B |
| 당기순이익 | - | $698.0M | $1.59B | $1.85B | $2.90B |
| 잉여현금흐름 (FCF) | - | $914.0M | $1.70B | $2.37B | $3.40B |
| 수익성 비율 | |||||
| 영업이익률 | - | 16.0% | 17.0% | 17.9% | 19.8% |
| 순이익률 | - | 5.5% | 11.2% | 11.1% | 14.4% |
| ROE (자기자본이익률) | - | 4.0% | 8.3% | 8.5% | 12.0% |
| ROA (자산이익률) | - | 2.1% | 4.5% | 4.7% | 6.6% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 12.3% | 17.6% | 19.9% |
| EPS 성장률 (YoY) | - | - | 137.8% | 16.8% | 55.2% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 102.8x | 59.1x | 81.9x | 48.2x |
| PBR (주가순자산배수) | - | 3.9x | 4.9x | 7.0x | 5.7x |
| PSR (주가매출배수) | - | 5.4x | 6.6x | 9.1x | 6.9x |
| FCF Yield | - | 1.3% | 1.8% | 1.6% | 2.4% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.53 | 0.49 | 0.49 | 0.47 |
| 유동비율 | - | 1.51 | 1.32 | 1.08 | 1.62 |
MOLINA HEALTHCARE INC
$179.86
$9.4B